JPMorgan Downgrades Synageva BioPharma (GEVA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Synageva BioPharma (GEVA) Misses Q1 EPS by 2c
February 26, 2015 5:04 PM ESTSynageva BioPharma (NASDAQ: GEVA) reported Q1 EPS of ($1.73), $0.02 worse than the analyst estimate of ($1.71).
For earnings history and earnings-related data on Synageva BioPharma (GEVA) click here.
... More